DOI:
10.1055/s-00023610
Drug Research
LinksClose Window
References
Zhang W, Krauwinkel WJ, Keirns J. et al.
The effect of moderate hepatic impairment on the pharmacokinetics of ipragliflozin, a novel sodium glucose co-transporter 2 (SGLT2) inhibitor.
Clin Drug Investig 2013;
33: 489-496
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.